ADVAGRAF + PROGRAF

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Renal Transplantation

Conditions

Renal Transplantation, Kidney Transplantation, Stable Renal Recipients

Trial Timeline

Apr 1, 2011 → Apr 1, 2013

NCT ID

NCT01742676

About ADVAGRAF + PROGRAF

ADVAGRAF + PROGRAF is a approved stage product being developed by Astellas Pharma for Renal Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01742676. Target conditions include Renal Transplantation, Kidney Transplantation, Stable Renal Recipients.

What happened to similar drugs?

20 of 20 similar drugs in Renal Transplantation were approved

Approved (20) Terminated (0) Active (0)

✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved

✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved

✅Tacrolimus, Prograf®Astellas PharmaApproved

✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved

✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved

✅Tacrolimus + CyclosporineAstellas PharmaApproved

✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03216447	Approved	UNKNOWN	Nov 23, 2017	Sep 30, 2025	Liver Transplantation
NCT02251691	Approved	UNKNOWN	May 9, 2014	Mar 31, 2020	Adherence to Medication Regime
NCT02268201	Approved	Terminated	Jul 23, 2013	Mar 31, 2015	Kidney Transplant Recipients
NCT01332201	Phase 2	Completed	Jul 1, 2011	Nov 1, 2013	Heart Transplantation
NCT01742676	Approved	Completed	Apr 1, 2011	Apr 1, 2013	Renal Transplantation

Competing Products

20 competing products in Renal Transplantation

See all competitors

Product	Company	Stage	Hype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109	MBX Biosciences	Phase 1	23
LY3473329	Eli Lilly	Phase 1	29
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
SPR001	Spruce Biosciences	Phase 2	25
SPR001	Spruce Biosciences	Phase 2	25
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
Tildacerfont	Spruce Biosciences	Phase 2	17
Drotrecogin alfa activated (Xigris)	Eli Lilly	Phase 2	35
LY3819469	Eli Lilly	Phase 1	29
Atezolizumab + Cabozantinib	Chugai Pharmaceutical	Phase 3	32
DS-6000a + DS-6000a	Daiichi Sankyo	Phase 1	33
DS-1093a	Daiichi Sankyo	Phase 1	29
CS-3150	Daiichi Sankyo	Phase 3	40
AGS-16C3F	Astellas Pharma	Phase 1	29
AGS-16M8F	Astellas Pharma	Phase 1	29
CP-461	Astellas Pharma	Phase 2	35
roxadustat	Astellas Pharma	Phase 3	40
YM178	Astellas Pharma	Phase 1	29
intravenous immunoglobulins (IVIG)	Astellas Pharma	Phase 1	29
bixalomer	Astellas Pharma	Pre-clinical	26